A Phase 4 interventional study of trospium chloride and placebo in Overactive Bladder, sponsored by Allergan. Completed at 1 site in United States. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-09-26.
Sponsored by Allergan (part of AbbVie) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Urinary Bladder, Overactive by AbbVie — none open to participants now, none under way, none of them phase 3. Urinary Bladder, Overactive · AbbVie.
Among the 28 studies in Urinary Bladder, Overactive by AbbVie, this one is the 9th largest by enrollment of the 22 interventional ones that give a count, is one of 4 that started in 2010, is one of 9 in phase 4, and was the 15th registered.
859 studies on the registry are indexed under Urinary Bladder, Overactive; 127 are open to participants now.
Browse Urinary Bladder, Overactive studies →None of the 28 studies in Urinary Bladder, Overactive by AbbVie is open now. The open studies under Urinary Bladder, Overactive, anywhere →
Of the 74 Urinary Bladder, Overactive studies recruiting now, 44 (59%) set no upper age limit and 16 (22%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 75 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 4 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 322 is above the median of 70 across 650 interventional studies indexed under Urinary Bladder, Overactive.
Median enrollment 265 across the 22 interventional studies, 447 across the 6 observational. Of the 28 that completed or were terminated, 20 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 28 studies in Urinary Bladder, Overactive by AbbVie, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will investigate the safety and efficacy of Sanctura XR (trospium chloride) daily in reducing urgency, urinary frequency and urinary urge incontinence in female patients with incontinence refractory to Detrol LA (tolterodine tartrate extended release) 4 mg therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Sanctura XR® (trospium chloride) 60 mg once daily on an empty stomach for 14 weeks.
Drug: trospium chloride
Placebo once daily on an empty stomach for 14 weeks.
Drug: placebo
Sanctura XR® (trospium chloride) 60 mg once daily on an empty stomach for 14 weeks
Also known as: Sanctura XR®
Placebo once daily on an empty stomach for 14 weeks.
Percentage of Patients Continent (PPC)
PPC is the percentage of patients with complete continence (without any urgency urinary incontinence episodes) during the 3-day bladder diary period associated with the Week 14 visit.
Time frame: Week 14
Change From Baseline in Continent Days Per Week (CDW)
Continent Days per Week is the average of the number of times an individual has no incontinence episodes in a day within the 3-day collection period calculated as 7 x (number of dry days within the 3-day diary period) divided by the number of valid diary days with at least one valid bladder diary entry during the 3-day period. A positive change from Baseline (more continent/fewer incontinent days per week ) indicated improvement.
Time frame: Baseline, Week 14
Change From Baseline in Nocturic Toilet Voids
A nocturic (nighttime) toilet void is identified if the patient marks "Yes" for both Toilet Voiding and Sleep Interruption in the 3-day bladder diary. The daily average number of nocturic toilet voids is obtained as the sum of all nighttime toilet voids over the 3-day bladder diary period divided by number of valid diary days with at least one valid bladder diary entry during the 3-day period. A negative change from Baseline (fewer nocturic toilet voids) indicated improvement.
Time frame: Baseline, Week 14
Change From Baseline in Urgency-Related Toilet Voids
Urgency-related toilet void (or urinary urgency) is identified if the patient marks "Yes" for both Urgency Association Void and Toilet Voiding in the 3-day bladder diary. The daily average number of urgency-related voids is calculated as the sum of all urgency episodes over the 3-day bladder diary period divided by the number of valid diary days with at least one valid bladder diary entry during the 3-day period. A negative change from Baseline (fewer urgency related toilet voids) indicated improvement.
Time frame: Baseline, Week 14
Change From Baseline in Daily Average Overactive Bladder-Symptom Composite Score (OAB-SCS)
The OAB-SCS is derived from the 3-day bladder diary which includes: 1) 24-hour voiding frequency; 2) the Indevus Urgency Severity Scale (IUSS) Score (0=no urgency, 1=aware of urgency but is tolerable, 2=urgency discomfort interferes with activities/tasks, 3=extreme urgency discomfort that abruptly stops activities/tasks associated with each toilet void); and 3) the frequency of Urgency Urinary Incontinence episodes. Each toilet void is then assigned a point value from 1 (IUSS Score=0) to 5 (UUI episode not associated with a toilet void). The daily average OAB-SCS is then calculated based on the diary entries and assigned point values. The lowest possible daily average OAB-SCS is 0 (corresponding to no urgency in every void). There is no upper limit since the score is based on the number of voids per day. Scores \<= 30 indicate mild OAB, scores \> 30 to 39 indicate moderate OAB, and scores \>= 40 indicate severe OAB. A negative change from Baseline indicated improvement.
Time frame: Baseline, Week 14
Change From Baseline in Voided Volume
Average volume of urine voided per toilet void is calculated by total volume collected in a 24-hour diary period divided by the number of individual entries of volume voided in that period. A positive change from Baseline (greater volume voided) indicated improvement. A negative change from Baseline (less volume voided) indicated a worsening.
Time frame: Baseline, Week 14
Change From Baseline in Urgency Severity
The urgency severity per toilet void is based on the Indevus Urgency Severity Scale (IUSS). The patient recorded urinary urgency severity in a 3-day bladder diary using a 4-point scale: 0=None-no urgency (best), 1=Slight-aware of urgency but is tolerable, 2=Moderate-urgency discomfort interferes with activities/tasks, 3=Severe-extreme urgency discomfort that abruptly stops activities/tasks (worst). Urgency Severity is calculated as the sum of all IUSS scores during the 3-day diary period divided by the number of toilet voids recorded during that period. A negative change from Baseline indicated improvement.
Time frame: Baseline, Week 14
Change From Baseline in Urgency Urinary Incontinence (UUI)
Urgency urinary incontinence is identified if the patient marks "Yes" for both Accidental Leakage and Urgency Associated Void in the 3-day bladder diary, and the Urgency Severity score is ≥ 1. Average daily episodes of UUI is calculated as the sum of all UUI episodes over 3-day diary period divided by the number of valid diary days with at least one valid bladder diary entry during the 3-day period. A negative change from Baseline indicated improvement.
Time frame: Baseline, Week 14
| Milestone | Sanctura XR® | Placebo |
|---|---|---|
| Started | 163 | 159 |
| Completed | 129 | 132 |
| Not completed | 34 | 27 |
PPC is the percentage of patients with complete continence (without any urgency urinary incontinence episodes) during the 3-day bladder diary period associated with the Week 14 visit.
| Percentage of participants | Sanctura XR® | Placebo |
|---|---|---|
| Percentage of Patients Continent (PPC) | 34.6 | 17.1 |
Continent Days per Week is the average of the number of times an individual has no incontinence episodes in a day within the 3-day collection period calculated as 7 x (number of dry days within the 3-day diary period) divided by the number of valid diary days with at least one valid bladder diary entry during the 3-day period. A positive change from Baseline (more continent/fewer incontinent days per week ) indicated improvement.
| Continent days per week | Sanctura XR® | Placebo |
|---|---|---|
| Baseline | 0.8 ± 1.46 | 1.0 ± 1.52 |
| Change from Baseline at Week 14 | 2.6 ± 2.96 | 1.3 ± 2.73 |
A nocturic (nighttime) toilet void is identified if the patient marks "Yes" for both Toilet Voiding and Sleep Interruption in the 3-day bladder diary. The daily average number of nocturic toilet voids is obtained as the sum of all nighttime toilet voids over the 3-day bladder diary period divided by number of valid diary days with at least one valid bladder diary entry during the 3-day period. A negative change from Baseline (fewer nocturic toilet voids) indicated improvement.
| Nocturic toilet void | Sanctura XR® | Placebo |
|---|---|---|
| Baseline | 2.2 ± 1.40 | 2.3 ± 1.41 |
| Change from Baseline at Week 14 | -0.6 ± 1.51 | -0.3 ± 1.42 |
Urgency-related toilet void (or urinary urgency) is identified if the patient marks "Yes" for both Urgency Association Void and Toilet Voiding in the 3-day bladder diary. The daily average number of urgency-related voids is calculated as the sum of all urgency episodes over the 3-day bladder diary period divided by the number of valid diary days with at least one valid bladder diary entry during the 3-day period. A negative change from Baseline (fewer urgency related toilet voids) indicated improvement.
| Toilet void | Sanctura XR® | Placebo |
|---|---|---|
| Baseline | 7.6 ± 3.36 | 7.5 ± 3.62 |
| Change from Baseline at Week 14 | -2.3 ± 3.78 | -1.6 ± 3.87 |
The OAB-SCS is derived from the 3-day bladder diary which includes: 1) 24-hour voiding frequency; 2) the Indevus Urgency Severity Scale (IUSS) Score (0=no urgency, 1=aware of urgency but is tolerable, 2=urgency discomfort interferes with activities/tasks, 3=extreme urgency discomfort that abruptly stops activities/tasks associated with each toilet void); and 3) the frequency of Urgency Urinary Incontinence episodes. Each toilet void is then assigned a point value from 1 (IUSS Score=0) to 5 (UUI episode not associated with a toilet void). The daily average OAB-SCS is then calculated based on the diary entries and assigned point values. The lowest possible daily average OAB-SCS is 0 (corresponding to no urgency in every void). There is no upper limit since the score is based on the number of voids per day. Scores \<= 30 indicate mild OAB, scores \> 30 to 39 indicate moderate OAB, and scores \>= 40 indicate severe OAB. A negative change from Baseline indicated improvement.
| Score on a scale | Sanctura XR® | Placebo |
|---|---|---|
| Baseline | 24.6 ± 9.07 | 23.7 ± 10.70 |
| Change from Baseline at Week 14 | -6.5 ± 10.23 | -3.4 ± 11.44 |
Average volume of urine voided per toilet void is calculated by total volume collected in a 24-hour diary period divided by the number of individual entries of volume voided in that period. A positive change from Baseline (greater volume voided) indicated improvement. A negative change from Baseline (less volume voided) indicated a worsening.
| cubic centimeters (cc) | Sanctura XR® | Placebo |
|---|---|---|
| Baseline | 183.5 ± 79.78 | 187.4 ± 78.76 |
| Change from Baseline at Week 14 | 20.6 ± 89.62 | -8.0 ± 71.56 |
The urgency severity per toilet void is based on the Indevus Urgency Severity Scale (IUSS). The patient recorded urinary urgency severity in a 3-day bladder diary using a 4-point scale: 0=None-no urgency (best), 1=Slight-aware of urgency but is tolerable, 2=Moderate-urgency discomfort interferes with activities/tasks, 3=Severe-extreme urgency discomfort that abruptly stops activities/tasks (worst). Urgency Severity is calculated as the sum of all IUSS scores during the 3-day diary period divided by the number of toilet voids recorded during that period. A negative change from Baseline indicated improvement.
| Score on a scale | Sanctura XR® | Placebo |
|---|---|---|
| Baseline | 1.4 ± 0.60 | 1.3 ± 0.56 |
| Change from Baseline at Week 14 | -0.4 ± 0.67 | -0.3 ± 0.60 |
Urgency urinary incontinence is identified if the patient marks "Yes" for both Accidental Leakage and Urgency Associated Void in the 3-day bladder diary, and the Urgency Severity score is ≥ 1. Average daily episodes of UUI is calculated as the sum of all UUI episodes over 3-day diary period divided by the number of valid diary days with at least one valid bladder diary entry during the 3-day period. A negative change from Baseline indicated improvement.
| UUI episodes | Sanctura XR® | Placebo |
|---|---|---|
| Baseline | 2.9 ± 2.99 | 3.0 ± 2.72 |
| Change from Baseline at Week 14 | -1.1 ± 2.24 | -0.6 ± 2.22 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sanctura XR® | — | 2/162 (1.2%) | 20/162 (12.3%) |
| Placebo | — | 3/158 (1.9%) | 8/158 (5.1%) |
| Event | Sanctura XR® | Placebo |
|---|---|---|
| Pericardial effusionCardiac disorders | 0/162 | 1/158 |
| Pyelonephritis acuteInfections and infestations | 0/162 | 1/158 |
| Diabetes mellitusMetabolism and nutrition disorders | 0/162 | 1/158 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/162 | 1/158 |
| AnaemiaBlood and lymphatic system disorders | 1/162 | 0/158 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 1/162 | 0/158 |
| GastroenteritisInfections and infestations | 1/162 | 0/158 |
| Event | Sanctura XR® | Placebo |
|---|---|---|
| Dry mouthGastrointestinal disorders | 11/162 | 6/158 |
| ConstipationGastrointestinal disorders | 9/162 | 2/158 |
| Age Continuous(Years) | Sanctura XR® | Placebo | Total |
|---|---|---|---|
| Mean | 56.3 (21 to 76) | 56.0 (21 to 84) | 56.1 (21 to 84) |
| Sex: Female, Male(Participants) | Sanctura XR® | Placebo | Total |
|---|---|---|---|
| Female | 163 | 159 | 322 |
| Male | 0 | 0 | 0 |
The record gives a start of Mar 2010, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2013, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trospium chloride